Simple Summary Pediatric mixed-phenotype leukemia is a rare form of blood cancer in
children. In this review, we cover both the evolution of treatment over the past several years …

Objectives Classification of acute leukemia involves assigning lineage by resemblance to
normal progenitor cells. This approach provides descriptive information about the blast cells …

Mixed-phenotype acute leukemia (MPAL) is a rare disease. Treatment is often similar to that
of acute lymphoblastic leukemia (ALL), but the outcome in adults and the role of allogeneic …

Background Chemotherapy is the foremost treatment for children with leukemia, while
causing different serious side-effects. Chemotherapy-induced nausea and vomiting are the …

Mixed phenotype (MP) in acute leukemias poses unique classification and management
dilemmas and can be seen in entities other than de novo mixed phenotype acute leukemia …

Mixed phenotype acute leukaemia (MPAL) is associated with worse overall survival,
compared with other acute leukaemias in adults. Lack of clear treatment guidelines makes …

Interventions: Despite undergoing 3 different acute lymphoblastic leukemia (ALL) regimens
and 1 acute myelogenous leukemia (AML) regimen, the patient did not achieve remission …

B/T mixed phenotype acute leukemia (MPAL), which represents only 2–3% of all MPAL
cases, is classified as a high-risk leukemia subtype. Adults diagnosed with B/T MPAL have a …

The optimal induction strategy for mixed phenotype acute leukemia (MPAL) is unknown,
though retrospective data has shown improved remission rates and overall survival with …

Outcomes for pediatric acute lymphoblastic leukemia (ALL) have improved dramatically
since the 1980s, now with approximately 90% survival at 5 years. Improved outcomes and …